Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Bruce J. Giantonio, Al B. Benson, Paul J. Catalano et al.|Journal of Clinical Oncology|2007Cited by 2.3k
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancersAparna R. Parikh, Ryan B. Corcoran, Ignaty Leshchiner et al.|Nature Medicine|2019Cited by 521
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal CancerAparna R. Parikh, Ryan B. Corcoran, Emily E. Van Seventer et al.|Clinical Cancer Research|2021Cited by 358
High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200Bruce J. Giantonio, Al B. Benson, Paul J. Catalano et al.|Journal of Clinical Oncology|2005Cited by 344
Characteristics Associated With Differences in Survival Among Black and White Women With Breast CancerJeffrey H. Silber, Kevin R. Fox, Paul R. Rosenbaum et al.|JAMA|2013Cited by 306